Ramifications of Cabotegravir's Pharmacokinetic Tail

Cabotegravir levels after the last dose remain detectable longer in women than in men and in those with greater body mass.

Long-acting antiretroviral drugs are of intense interest for HIV treatment as well as PrEP. In HPTN 077, a placebo-controlled phase IIa trial conducted at eight international sites, researchers evaluated the safety and pharmacokinetics of a long-acting (LA) intramuscular (IM) formulation of the integrase inhibitor cabotegravir. HIV-negative subjects were randomized 3:1 to receive either of two IM regimens (three 800-mg doses every 12 weeks or five 600-mg doses for one 4-week interval, then every 8 weeks) or IM placebo. Subjects were followed for up to 76 weeks after the last injection. This prespecified analysis focused on the pharmacokinetic tail phase after the last IM dose. In all, 134 participants in the cabotegravir arms and 43 in the …

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Ramifications of Cabotegravir's Pharmacokinetic Tail

Topics

Reviewing Author